| Login | Support

Press Release

Intelligent Medical Objects Announces Sale of Virtual DBA™ Database Analysis Application to Quest Software

04/12/2000

Dallas, Texas, April 12, 2000 - Intelligent Medical Objects (IMO), well-known for its expertise in point-of-care medical applications and vocabulary management, announces the sale of its advanced database analysis software, Virtual DBA™, to Quest Software, Inc.

Virtual DBA (VDBA) packages actions and common procedures that are on everyone's wish list when dealing with an install base of many similar databases. It offers a view into the structural definition of a relational database schema and provides feedback on a myriad of database properties. VDBA allows for reverse engineering of database schemas, analysis of database design flaws, automatic creation of build scripts, comparison between database schemas with creation of migration scripts, and many other valuable functions. It provides full support for Oracle's Oracle7 and Oracle8(ORCL) databases, Microsoft SQL Server™ 6.5 (MSFT) databases, in addition to generic ODBC databases.

Quest Software is an industry leader in providing application, information and database availability software solutions that not only enhance the performance and reliability of an organization's e-business, enterprise and custom computing applications but enhance the delivery of information across the entire enterprise. "We plan to incorporate the functionality of the Virtual DBA product in our popular TOAD application development tools because it automates many complex tasks that DBAs need to accomplish," said Jim McDaniel, Quest development manager.

By applying the best of what computer science technology offers, the IMO team delivers knowledge management and information management tools with particular expertise in the healthcare area. "Virtual DBA reveals our technology competence. Its sale demonstrates how IMO is able to take tools developed to manage complex health information systems and package them to be used outside of healthcare," says Frank Naeymi-Rad, Ph.D., President of IMO. IMO has over ten years experience in developing health information systems and electronic medical records.

IMO's current focus is in the development of application tools for the Internet. "This sale allows IMO to focus on the next generation of its tools, supporting intelligent search portals, XML database access and XSL client independent user interfaces," says Regis Charlot V.P. of Development and author of the VDBA. The company's next flagship technology product is "RAD" (Rapid Application Development suite) which is based on an adaptive data model, flexible user interface and a flexible rules engine. This tool has been used successfully by Lucent Technologies (LU), QuadraMed Corporation (QMDC), and recently in developing the next generation adaptive and intelligent medical record system: O-HEAP (Orientation, History, Exam, Assessment and Plan).

"IMO is certainly not abandoning healthcare. Relationships such as this with Quest Software demonstrates to our healthcare partners IMO's value as a technology leader as well as a medical application expert.  Our upcoming intelligent healthcare search portal and PHT™ (Personal Health Terminology) is another example of IMO's computer science know- how used to enhance access to health information and consumer- professional communication," says Dr. Andrew Kanter, IMO Chief Operating Officer.

Intelligent Medical Objects is a Chicago based firm with a core team consisting of medical doctors, software developers and engineers. IMO produces components, tools applications and web sites. For more information about IMO's RAD suite, Personal Health Terminology or other IMO products and consulting call 888-466-6246 or visit IMO's web site at http://www.imo-online.com.

Quest Software, Inc. delivers solutions that enhance the performance and reliability of e-business, packaged and custom computing applications. Based in Irvine, Calif., Quest Software has sales and support offices worldwide staffed by more than 800 employees.